Inspire Medical Systems, Inc.

Day range

$70.00 – $72.40

Open

$70.51

Prev close

$71.11

Volume

184.11K

Market cap

$2.06B

Shares out

28.91M

P/E

15.22

P/S

2.29

P/B

2.49

P/FCF

17.56

ROE

16.4%

ROA

14.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationAug 3, 2026

  In August and September of 2026, the Company will be participating in various meetings with investors and analysts, and a copy of the Company's presentation materials being used at these meetings is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

• Director appointmentJul 24, 2026

  On July 20, 2026, the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michael H. Carrel to the Board, effective immediately. Mr. Carrel will serve as a Class III director for a term expiring at the Company's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal. In connection with the appointment of Mr. Carrel to the Board, he was also appointed to serve on the Organization and Compensation Committee and Quality, Product Supply and Technology Committee.

• Director departureJul 22, 2026

  On July 16, 2026, Casey Tansey, a member of the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), notified the Company of his decision to retire from the Board (and the committees on which he serves) and not stand for re-election at the Company's 2027 Annual Meeting of Stockholders (the "2027 Annual Meeting"). Mr. Tansey's retirement will become effective July 30, 2026.

• Investor presentationJun 26, 2026

  In June 2026, the Company will be participating in various meetings with investors and analysts, and a copy of the Company's presentation materials being used at these meetings is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company's website at https://investors.inspiresleep.com.

• Equity compensation grantMay 5, 2026

  The approval of the A&R 2018 Plan by stockholders (i) authorized the issuance of 9,903,857 shares of the Company's common stock for awards under the A&R 2018 Plan, which includes 7,303,857 shares previously authorized for issuance under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan (the '2018 Plan'), plus an increase of 2,600,000 shares.

Days to cover

4.6

Short interest

4.2M

Avg volume

906.71K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
  positiveZacks Investment Research· Oct 23, 2026
• Here's How Tempus AI Demonstrates Improving Operating Leverage
  positiveZacks Investment Research· Oct 19, 2026
• Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Oct 6, 2026
• Here's Why You Should Retain INSP Stock in Your Portfolio for Now
  neutralZacks Investment Research· Sep 23, 2026
• Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
  positiveZacks Investment Research· Sep 18, 2026